A case is made for the involvement of pituitary prostaglandins (PGs) in the regulation of thyrotropin (TSH) secretion by citing recent evidence that TSH release in vivo and in vitro is enhanced by treatment with exogenous PGs and is inhibited by drugs (e.g., indomethacin) that block PG synthesis. Pharmacological studies were then performed to test the hypothesis that hypothalamic PGs also affect TSH secretion indirectly via the appropriate hypothalamic hormones that regulate pituitary secretion. The inhibition of thyroidectomy-induced TSH secretion was used as an endpoint in choosing the best of several drugs purported to inhibit PG synthesis. The established effectiveness of indomethacin and aspirin were used for reference in testing the following drugs: naproxen, mefenamic acid, tranylcypromine, and phenelzine. Only naproxen was found to be effective, but since it was no more potent than indomethacin, the latter drug was used for subsequent work. Indomethacin was stereotaxically implanted into several hypothalamic regions known to regulate TSH secretion, and sequential plasma samples were analyzed for TSH by radioimmunoassay. Bilateral implants of indomethacin in the anterior hypothalamic area increased TSH secretion throughout the 72 hr period of study. Sham inplants at this site and indomethacin implants in other nearby sites were ineffective. These findings suggest that endogenous PGs play an inhibitory role in the hypothalamic regulation of pituitary secretion.
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Over the past couple of decades it has become well recognized that the prostaglandins (PGs) can exert a wide variety of endocrine and metabolic effects. In particular, these ubiquitous fatty acids have recently been shown to affect the secretion of each of the hormones of the anterior pituitary gland (1, 2) . In some instances, the effects of the PGs are direct ones in that they affect the pituitary itself. In contrast, others of the known effects are indirect in that they are exerted at the hypothalamus on factors which in turn alter pituitary secretion. Figure 2 demonstrates that indomethacin (three subcutaneous injections of 3 mg each during the first 24 hr) virtually abolishes the compensatory increase in plasma TSH levels following surgical thyroidectomy. Similar results are seen when using aspirin instead of the indomethacin, but higher doses are required. It is also worth noting that the normal rise in TSH is seen after the effect ofthe indomethacin disappears, indicating that the effect is not due to some type of irreversible tissue damage.
In contrast to the well documented pituitary effects of PGs regarding TSH secretion, only few 84 studies have investigated the possibility of an indirect effect at some suprapituitary site. Our own studies (4) and those of others (8) induced TSH secretion. This rather simple protocol was very appropriate for screening, and it very clearly showed the effects of indomethacin and aspirin in our previous studies. Based on the known potencies relative to indomethacin in other systems, we chose the following drugs at the doses indicated in the legend of Figure 3 : naproxen (Naprosyn), mefenamic acid (Ponstel), tranylcypromine sulfate (Parnate), phenelzine sulfate (Nardil). Female rats were thyroidectomized under ether and injected sc at the indicated doses three times over a 24 hr period as in the case of the earlier studies with indomethacin and aspirin. At the times indicated in Figure 3 , blood samples were obtained from tail veins under light ether anesthesia for subsequent radioimmunoassay for TSH and T4. As seen in the lower panel of Figure 3 , only naproxen inhibited thyroidectomy-induced TSH secretion (p < 0.05 at 24 hr, and p < 0.01 at 96 hr). Each of the other drugs tested in this series was without effect.
Before concluding that naproxen blocks TSH secretion directly, it was necessary to show that the observed effect is not secondary to some change in the rate at which T4is cleared after thyroidectomy. That is, it was possible that the drug could increase the half-life of T4 resulting in plasma T4 levels that were higher than control during the treatment and thus the lower TSH level might be due to the normal function of the negative feedback mechanism. This possibility is ruled out by the T4 data shown above the TSH data for the control and naproxen groups at all times studied ( Figure 3 ). Even though naproxen has this inhibitory effect, it is clearly no better than indomethacin in this regard. Thus, we decided to use indomethacin in our subsequent study of the possible involvement of hypothalamic PGs in regulating TSH secretion. The systemic administration of PGs or drugs that alter PG economy is acceptable for screening studies, but given the ubiquitous distribution of the PGs, such a route of injection could result in numerous side effects and thus yield data which are virtually uninterpretable. With this in mind, we chose to test for hypothalamic effects of indomethacin by stereotaxically implanting small amounts of it (45 ,ug, or talc as control) into specific areas of the hypothalamus known to be involved in the regulation of TRH and TSH secretion. In these studies, it was imperative that we administer the indomethacin 86 locally since we already knew that the drug could decrease pituitary responsiveness to TRH, and we had to use plasma TSH as an endpoint in such studies. These implants were made in pentobarbital-anesthetized (4.5 mg/100 g body weight) female rats. Subsequent blood samples were obtained by cardiac puncture under light ether anesthesia. Figure 4 depicts diagramatically the areas of interest in this experiment, and it indicates the responsive and the unresponsive regions. Pilot experiments involving single pellets on the midline suggested that such implants might increase TSH secretion, but the differences were not statistically significant. However, when bilateral implants were placed in the anterior hypothalamic area (centered 0.6 mm to each side of midline), significant increases in TSH secretion were observed at all times studied (Fig. 5) . Control implants of talc pellets had no such effect. As would be expected the absolute TSH concentrations at time zero (before implantation) in the two groups did not differ. Identical implants of indomethacin placed approximately one mm anterior to this region (Fig. 4 , cross-hatched area) were without effect. Somewhat to our surprise, such implants in the medial basal hypothalamus (Fig. 4, stippled area) regulating TSH secretion, this result may be due to the fact that this region primarily contains fibers rather than cell bodies. The results of our earlier pharmacological studies showing that indomethacin decreases TSH secretion in response to stimulation by either TRH or the removal of thyroid hormone feedback suggest that anterior pituitary PGs enhance TSH secretion. In contrast, the present results suggest that PGs of the hypothalamus decrease TSH (presumably via increasing TRH). These findings provide an interesting contrast to the case of ACTH where it is known that indomethacin in the hypothalamus decreases stress-induced ACTH secretion (14) , whereas indomethacin in the anterior pituitary increases ACTH responsiveness to a CRF preparation (15) . In the latter case, it has also been shown that the effect of indomethacin was due to its limiting the availability of PGs since exogenous PGs completely reversed this effect of the drug.
The overall picture that emerges regarding the hypothalamic and pituitary effects of PGs on TSH and ACTH secretion is depicted in Figure 6 . In the case of each of these tropic hormones, the effect of the PGs at the pituitary is of opposite polarity to the suprapituitary effect. It can also be seen that at each anatomical level the effect of the PGs on TSH is the opposite of the one on ACTH. Of the four PG effects depected on Figure 6, far as we are aware, the present study with indomethacin is the only one to have investigated this hypothalamic involvement of PGs in TSH secretion. This reciprocity is reminiscent of the "inverse relationship" often described regarding the regulation of these two pituitary hormones (16) . Although this interaction was originally thought to be a pituitary phenomenon, it has been suggested more recently that the interaction may occur above the pituitary. It is interesting to speculate that the reciprocal effects of the prostaglandins could participate in mediating such a relationship at either or both of these levels.
The results of the present study are consistent with the notion that some prostanoid can inhibit TSH secretion by the pituitary indirectly by acting in the region of the anterior hypothalamus. However, to be accepted as firm evidence for this notion, 87 the effect of the indomethacin would have to be known to be due to its inhibition of PG synthesis, rather than to any of a host of other potential effects of the drug. This distinction could be made by experiments demonstrating that the addition of exogenous PGs will reverse the effect of the drug. Another aspect of the present work that requires further attention concerns the fact that indomethacin blocks synthesis at a very early step (the cyclooxygenase step), and thus prevents the production of virtually all members of the prostaglandin family. Although there was good reason to begin this work with the pharmacological approach, the results obviously do not provide the identity of the specific prostaglandin(s) that normally plays this inhibitory role in the hypothalamus. However, this information could also emanate from the experiments just proposed, and would provide an important confirmation of our interpretation of our present results.
